Q-omics provides the consensus-scored MIR130A profile across patient tissues and cancer cell-line models. MIR130A expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, MIR130A is differentially expressed in 1, with the highest sampling consensus in BRCA. Additionally, MIR130A RNA expression shows 10,643 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, BRCA, and THYM as cancer lineages where MIR130A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR130A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR130A survival associations across molecular data types. MIR130A RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR130A RNA expression–survival associations across cancer types. High MIR130A expression shows unfavorable associations in READ, ACC and UCEC, but favorable associations in CESC, GBM and ESCA. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify CESC as the clearest survival context for MIR130A RNA expression.
This table summarizes MIR130A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR130A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR130A shows lower tumor expression in BRCA. The BRCA box plot shows higher MIR130A RNA expression in normal versus tumor tissue (log2 FC = −0.188, t-test p = .002).
This table shows molecular features associated with MIR130A in patient tissues and cancer cell lines. In patient samples, MIR130A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
